Corpus overview


Overview

MeSH Disease

Fever (725)

Coronavirus Infections (316)

Cough (270)

Infections (252)

Dyspnea (219)


Human Phenotype

Fever (829)

Cough (523)

Pneumonia (198)

Fatigue (181)

Dyspnea (117)


Transmission

age categories (427)

gender (265)

Transmission (139)

fomite (128)

asymptotic cases (123)


Seroprevalence
    displaying 1 - 10 records in total 829
    records per page




    PREVALENCE SERO OF ANTIBODIES SERO AGAINST SARS-CoV-2 IN MESHD PROFESSIONALS OF A PUBLIC HEALTH LABORATORY AT SAO PAULO, SP, BRAZIL

    Authors: Valeria Oliveira Silva; Elaine Lopes de Oliveira; Marcia Jorge Castejon; Rosemeire Yamashiro; Cintia Mayumi Ahagon; Giselle Ibette Lopez-Lopes; Edilene Peres Real da Silveira; Marisa Ailin Hong; Maria do Carmo Timenetsky; Carmem aparecida de Freitas Oliveira; Luis Fernando de Macedo Brigido; Satish Lakkakula; Oren Miron; Ehud Rinott; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20213421 Date: 2020-10-21 Source: medRxiv

    Background: Covid-19 Serology may document exposure and perhaps protection to the virus, and serological test SERO may help understand epidemic dynamics. To evaluate previous exposure to the virus we estimated the prevalence SERO of antibodies SERO against-SARS-CoV-2 among HPs in Adolfo Lutz Institute, State of Sao Paulo, Brazil. Methods: This study was performed among professionals of Adolfo Lutz Institute in Sao Paulo, Brazil and some administrative areas of the Secretary of Health that shares common areas with the institute. We used a lateral flow immunoassay SERO ( rapid test SERO) to detect IgG and IgM for SARS-CoV-2; positive samples were further evaluated using Roche Electrochemiluminescence assay and SARS-CoV-2 RNA by real time reverse transcriptase polymerase chain reaction (RT-PCR) was also offered to participants. Results: A total of 406 HPs participated. Thirty five (8.6%) tested positive on rapid test SERO and 32 these rapid test SERO seropositive cases were confirmed TRANS by ECLIA.. 43 HPs had SARS-CoV-2 RNA detected at a median of 33 days, and the three cases not reactive at Roche ECLIA had a previous positive RNA. Outsourced professionals (34% seropositive), males TRANS (15%) workers referring COVID-19 patients at home (22%) and those living farther form the institute tended to have higher prevalence SERO of seropositivity, but in multivariable logistic analysis only outsourced workers and those with COVID patients at home remained independently associated to seropositivity. We observed no relation of seropositivity to COVID samples handling. Presence of at least one symptom was common but some clinical manifestations as anosmia HP anosmia MESHD/dysgeusia. Fatigue HP, cough HP cough MESHD and fever HP fever MESHD were associated to seropositivity. Conclusions: We documented a relatively high (8.6%) of anti-SARS-CoV-2 serological reactivity in this population, with higher rates among outsourced workers and those with referring cohabitation with COVID-19 patients. COVID samples handling was not related to increased seropositivity. Some symptoms how strong association to COVID-19 serology and may be used in scoring tools for screening or diagnosis in resort limited settings.

    Tocilizumab is associated with reduction in inflammation MESHD and improvement in P/F ratio in critically sick COVID19 patients

    Authors: Muhammad Asim Rana; Mubashar Sultan Hashmi; Muhammad Muneeb Ullah Saif; Muhammad Faisal Munir; Ahad Qayyum; Rizwan Pervaiz; Muhammad Mansoor Hafeez; Graham Cooke; Timothy B Hallett; Katharina D Hauck; Peter J White; Mark R Thursz; Shevanthi Nayagam; Brendan Flannery; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20210195 Date: 2020-10-21 Source: medRxiv

    Introduction: Coronavirus disease 2019 was initially detected in China and has been declared a global pandemic by World Health Organization on March 11, 2020. In the majority of patients, SARS-CoV-2 causes a mild to moderate illness characterized by fever HP fever MESHD and respiratory symptoms MESHD, with or without evidence of pneumonia HP pneumonia MESHD. The recent studies suggest that anti-cytokine targeted therapies might be associated with benefit for patients with severe COVID-19 especially in improving respiratory failure HP respiratory failure MESHD. Tocilizumab, a monoclonal antibody SERO against interleukin 6 (IL6) receptor, is associated with clinical benefit for COVID-19 patients as it inhibits IL6 and decreases inflammation MESHD. Methods: As Tocilizumab has been an important part of our treatment and a strict criterion was followed to administer Tocilizumab, a retrospective study design used to assess the beneficial effects of Tocilizumab in improvement of ratio partial pressure of arterial Oxygen and fraction of inspired Oxygen (PaO2/FiO2 or P/F ratio) and C- reactive protein (CRP) in COVID19 patients has been done. 60 patients were taken for this study by using convenient sampling technique the data of demographics, laboratory results, and clinical outcomes i.e. improvement of respiratory failure HP respiratory failure MESHD depicted in the form of PF Ratio were obtained from the medical records, Statistical analysis was done with SPSS, version 21.0. Results: Sixty patients (47 males TRANS and 13 females TRANS) with COVID-19 were included in this study, the mean age TRANS of patients was 53.83 (14-81) years. After administration of Tocilizumab the lab parameters were changed as CRP decreased down to .40 (9.6-73) mg/L but other parameters were not affected. The PF ratio improved in COVID-19 patients after administration of Tocilizumab the median of PF Ratio before treatment was 108 (52-362) and improved up to 128 (37-406) after Tocilizumab therapy. Conclusion: In summary, Tocilizumab appears to be associated with improvement in P/F Ratio and CRP in COVID19 patients but other markers did not improve in response to Tocilizumab therapy in severely ill COVID-19 patients.

    Prevalence SERO of SARS-CoV-2 IgG antibodies SERO in a population from Veracruz (Southeastern Mexico).

    Authors: Jose Maria Remes-Troche; Antonio Ramos-de-la-Medina; Marisol Manriquez-Reyes; Laura Martinez-Perez Maldonado; Maria Antonieta Solis-Gonzalez; Karina Hernandez-Flores; Hector Vivanco-Cid; Graham Cooke; Timothy B Hallett; Katharina D Hauck; Peter J White; Mark R Thursz; Shevanthi Nayagam; Brendan Flannery; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20215558 Date: 2020-10-21 Source: medRxiv

    Introduction/Aim: Recent studies have shown that seroprevalence SERO is quite variable depending on the country, the population and the time of the pandemic in which the serological tests SERO are performed. Here, we investigated the prevalence SERO of IgG antibodies SERO against SARS-CoV-2 in a population living in Veracruz City, Mexico. Methods: From of June 1 to July 31, 2020, the consecutive adult TRANS patients that attended 2 ambulatory diagnostic private practice centers for testing were included. Samples were run on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG assay. The main outcome was seroprevalence SERO. Demographics, previous infection MESHD to SARS-CoV-2 (according to a previous positive polymerase-chain reaction nasopharyngeal swab), self-suspicious of virus of infection MESHD (according to have in the previous 4 weeks either fever HP fever MESHD, headache HP headache MESHD, respiratory symptoms but not a confirmatory PCR) or no having symptoms were also evaluated. Results: A total of 2174 subjects were tested, included 53.6% women (mean age TRANS 41.8, range 18-98 years). One thousand and forty-one (52.5%) subjects were asymptomatic TRANS, 722 (33.2%) had suspicious of infection MESHD and 311 (14.3%) had previous infection MESHD. Overall, 642 of 2174 (29.5% [95% CI 27.59%-31.47%]) of our population were seropositive. Seropositivity among groups was 21.3% in asymptomatic TRANS, 23.4% in self-suspicious patients and 73.9% in previous infection MESHD patients. Conclusions: We found one of the highest seroprevalences SERO reported for SARS-CoV-2 worldwide in asymptomatic TRANS subjects (21.3%) as well in subjects with self-suspicious of COVID-19 (23.4%). The number of infected subjects in our population is not encouraging and it should be interpreted with caution.

    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

    Authors: Ayham Daher; Paul Balfanz; Maria Aetou; Bojan Hartmann; Dirk Müller-Wieland; Tobias Müller; Nikolaus Marx; Michael Dreher; Christian G Cornelissen

    doi:10.21203/rs.3.rs-95432/v1 Date: 2020-10-20 Source: ResearchSquare

    Purpose: Patients suffering from CVOID-19 mostly experience a benign course of the disease. Approximately 14 % of SARS-CoV2 infected MESHD patients are admitted to a hospital. Cohorts exhibiting severe lung failure MESHD in the form of acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) have been well characterized. Patients without ARDS MESHD but in need of supplementary oxygen have received much less attention. This study describes the diagnosis, symptoms, treatment and outcomes of hospitalized patients with COVID-19 needing oxygen support during their stay on regular ward.Methods: All 133 patients admitted to the RWTH Aachen university hospital with the diagnosis of COVID-19 were included in an observational registry. Clinical data sets were extracted from the hospital information system. This analysis includes all 57 patients requiring supplemental oxygen not admitted to the ICU.Results: 57 patients needing supplemental oxygen and being treated outside the ICU were analyzed. Patients exhibited the typical set of symptoms for COVID-19. Of note, hypoxic MESHD patients mostly did not suffer from clinically relevant dyspnea HP dyspnea MESHD despite oxygen saturations below 92 %. Patients had fever HP fever MESHD for 7 [2-11] days and needed supplemental oxygen for 8 [5-13] days resulting in an overall hospitalization time of 12 [7-20] days. In addition, patients had persisting systemic inflammation MESHD with CRP levels remaining elevated until discharge or death MESHD.Conclusion: This description of COVID-19 patients requiring oxygen therapy should be taken into account when planning treatment capacity. Patients on oxygen need long-term inpatient care.

    Systematic review of reviews of symptoms and signs of COVID-19 in children TRANS and adolescents

    Authors: Russell M Viner; Joseph Ward; Lee Hudson; Melissa Ashe; Sanjay Patel; Dougal Hargreaves; Elizabeth Whittaker; Seiichi Ichikawa; Daisuke Mizushima; Shingo Iwami; Ferenc E Mózes; Adam J Lewandowski; Eric O Ohuma; David Holdsworth; Hanan Lamlum; Myles J Woodman; Catherine Krasopoulos; Rebecca Mills; Flora A Kennedy McConnel; Chaoyue Wang; Christoph Arthofer; Frederik J Lange; Jesper Andersson; Mark Jenkinson; Charalambos Antoniades; Keith M Channon; Mayooran Shanmuganathan; Vanessa M Ferreira; Stefan K Piechnik; Paul Klenerman; Christopher Brightling; Nick P Talbot; Nayia Petousi; Najib M Rahman; Ling-Pei Ho; Kate Saunders; John R Geddes; Paul Harrison; Kyle Pattinson; Matthew J Rowland; Brian Angus; Fergus Gleeson; Michael Pavlides; Ivan Koychev; Karla L Miller; Clare Mackay; Peter Jezzard; Stephen M Smith; Stefan Neubauer

    doi:10.1101/2020.10.16.20213298 Date: 2020-10-18 Source: medRxiv

    Objective To undertake a systematic review of reviews of the prevalence SERO of symptoms and signs of COVID-19 in those aged TRANS under 20 years? Design Narrative systematic review of reviews. PubMed, medRxiv, Europe PMC and COVID-19 Living Evidence Database were searched on 9 October 2020. Setting All settings, including hospitalised and community settings. Patients CYP under age TRANS 20 years with laboratory-proven COVID-19. Study review, data extraction and quality Potentially eligible articles were reviewed on title and abstract by one reviewer. Quality was assessed using the modified AMSTARS criteria and data were extracted from included studies by two reviewers. Main outcome measures Prevalence SERO of symptoms and signs of COVID-19 Results 1325 studies were identified and 18 reviews were included. Eight were high quality, 7 medium and 3 low quality. All reviews were dominated by studies of hospitalised children TRANS. The proportion who were asymptomatic TRANS ranged from 14.6 to 42%. Fever HP Fever MESHD and cough HP cough MESHD were the commonest symptoms; proportions with fever HP fever MESHD ranged from 46 to 64.2% and with cough HP from 32 to 55.9%. All other symptoms or signs including rhinorrhoea, sore throat, headache HP headache MESHD, fatigue HP fatigue MESHD/ myalgia HP myalgia MESHD and gastrointestinal symptoms including diarrhoea and vomiting MESHD vomiting HP are infrequent, occurring in less than 10-20%. Conclusions Fever HP Fever MESHD and cough HP cough MESHD are the most common symptoms in CYP with COVID-19, with other symptoms infrequent. Further research on symptoms in community samples are needed to inform pragmatic identification and testing programmes for CYP.

    On Modeling of COVID-19 for the Indian Subcontinent using Polynomial and Supervised Learning Regression MESHD

    Authors: Dishita Neve; Honey Patel; Harsh S Dhiman; Victoria Acquaye; Alfred D. Dai-Kosi; Alejandro J Krolewiecki; Juan P Aparicio; Haifeng Wang; Dejing Dou; Pete Bond; Paul Anthony McAry; Sharad Bhagat; Itti Munshi; Swapneil Parikh; Sachee Agrawal; Chandrakant Pawar; Mala Kaneria; Smita Mahale; Jayanthi Shastri; Vainav Patel; Paul Dark; Alexander Mathioudakis; Kathryn Gray; Graham Lord; Timothy Felton; Chris Brightling; Ling-Pei Ho; - NIHR Respiratory TRC; - CIRCO; Karen Piper Hanley; Angela Simpson; John R Grainger; Tracy Hussell; Elizabeth R Mann

    doi:10.1101/2020.10.14.20212563 Date: 2020-10-16 Source: medRxiv

    COVID-19, a recently declared pandemic by WHO has taken the world by storm causing catastrophic damage MESHD to human life. The novel cornonavirus disease MESHD was first incepted in the Wuhan city of China on 31st December 2019. The symptoms include fever HP fever MESHD, cough HP cough MESHD, fatigue HP fatigue MESHD, shortness of breath MESHD or breathing difficulties, and loss of smell and taste. Since the devastating phenomenon is essentially a time-series representation, accurate modeling may benefit in identifying the root cause and accelerate the diagnosis. In the current analysis, COVID-19 modeling is done for the Indian subcontinent based on the data collected for the total cases confirmed TRANS, daily recovered, daily deaths, total recovered and total deaths. The data is treated with total confirmed cases TRANS as the target variable and rest as feature variables. It is observed that Support vector regressions yields accurate results followed by Polynomial regression. Random forest regression results in overfitting followed by poor Bayesian regression due to highly correlated feature variables. Further, in order to examine the effect of neighbouring countries, Pearson correlation matrix is computed to identify geographic cause and effect.

    Symptoms associated with SARS-CoV-2 infection MESHD in a community-based population: Results from an epidemiological study

    Authors: Brian E Dixon; Kara Wools-Kaloustian; William F Fadel; Thoomas J Duszynski; Constantin Yiannoutsos; Paul K Halverson; Nir Menachemi; Ayo-Maria Olofinuka; Vetty Agala; John Nwolim Paul; Doris Nria; Chinenye Okafor; Ifeoma Ndekwu; Chikezie Opara; Chris Newsom

    doi:10.1101/2020.10.11.20210922 Date: 2020-10-14 Source: medRxiv

    Background: Studies examining symptoms of COVID-19 are primarily descriptive and measured among hospitalized individuals. Understanding symptoms of SARS-CoV-2 infection MESHD may improve clinical screening, particularly during flu season. We sought to identify key symptoms and symptom combinations in a community-based population. Methods: We pooled statewide, community-based cohorts of individuals aged TRANS 12 and older screened for SARS-CoV-2 infection MESHD in April and June 2020. Main outcome was SARS-CoV-2 positivity. We calculated sensitivity SERO, specificity, positive predictive value SERO (PPV), and negative predictive value SERO (NPV) for individual symptoms as well as symptom combinations. We further employed multivariable logistic regression and exploratory factor analysis (EFA) to examine symptoms and combinations associated with SARS-CoV-2 infection MESHD. Results: Among 8214 individuals screened, 368 individuals (4.5%) were RT-PCR positive for SARS-CoV-2. Although two-thirds of symptoms were highly specific (>90.0%), most symptoms individually possessed a PPV <50.0%. The individual symptoms most greatly associated with SARS-CoV-2 positivity were fever HP fever MESHD (OR=5.34, p<0.001), anosmia HP anosmia MESHD (OR=4.08, p<0.001), ageusia MESHD (OR=2.38, p=0.006), and cough HP (OR=2.86, p<0.001). Results from EFA identified two primary symptom clusters most associated with SARS-CoV-2 infection MESHD: (1) ageusia, anosmia HP anosmia MESHD, and fever HP fever MESHD; and (2) shortness of breath MESHD, cough HP, and chest pain HP chest pain MESHD. Moreover, being non-white (13.6% vs. 2.3%, p<0.001), Hispanic (27.9% vs. 2.5%, p<0.001), or living in an Urban area (5.4% vs. 3.8%, p<0.001) was associated with infection MESHD. Conclusions: When laboratory testing is not readily accessible, symptoms can help distinguish SARS-CoV-2 infection MESHD from other respiratory viruses. Symptoms should further be structured in clinical documentation to support identification of new cases and mitigation of disease MESHD disease spread TRANS by public health. These symptoms, derived from mildly infected individuals, can also inform vaccine and therapeutic clinical trials.

    What is the evidence for transmission TRANS of COVID-19 by children TRANS in schools? A living systematic review

    Authors: Wei Xu; Xue Li; Marshall Dozier; Yazhou He; Amir Kirolos; Zhongyu Lang; Catherine Mathews; Nandi Siegfried; Evropi Theodoratou; Sasha N. L. Bailey; Stephen Talyor; Jessica Jones; Meleri Jones; Wing Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel J. Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA

    doi:10.1101/2020.10.11.20210658 Date: 2020-10-14 Source: medRxiv

    ABSTRACT Background: It is of paramount importance to understand the transmission TRANS of SARS-CoV-2 in schools, which could support the decision-making about educational facilities closure or re-opening with effective prevention and control measures in place. Methods: We conducted a systematic review and meta-analysis to investigate the extent of SARS-CoV-2 transmission TRANS in schools. We performed risk of bias evaluation of all included studies using the Newcastle- Ottawa Scale (NOS). Results: 2,178 articles were retrieved and 11 studies were included. Five cohort studies reported a combined 22 student and 21 staff index cases that exposed 3,345 contacts with 18 transmissions TRANS [overall infection MESHD attack rate TRANS (IAR): 0.08% (95% CI: 0.00%-0.86%)]. IARs for students and school staff were 0.15% (95% CI: 0.00%-0.93%) and 0.70% (95% CI: 0.00%-3.56%) respectively. Six cross-sectional studies reported 639 SARS-CoV-2 positive cases in 6,682 study participants tested [overall SARS-CoV-2 positivity rate: 8.00% (95% CI: 2.17%-16.95%)]. SARS-CoV-2 positivity rate was estimated to be 8.74% (95% CI: 2.34%-18.53%) among students, compared to 13.68% (95% CI: 1.68%-33.89%) among school staff. Gender TRANS differences were not found for secondary infection MESHD (OR: 1.44, 95% CI: 0.50-4.14, P= 0.49) and SARS-CoV-2 positivity (OR: 0.90, 95% CI: 0.72-1.13, P= 0.36) in schools. Fever HP Fever MESHD, cough HP cough MESHD, dyspnea HP dyspnea MESHD, ageusia MESHD, anosmia HP anosmia MESHD, rhinitis HP rhinitis MESHD, sore throat, headache HP headache MESHD, myalgia HP myalgia MESHD, asthenia HP asthenia MESHD, and diarrhoea MESHD were all associated with the detection of SARS-CoV-2 antibodies SERO (based on two studies). Overall, study quality was judged to be poor with risk of performance SERO and attrition bias MESHD, limiting the confidence in the results. Conclusions: There is limited high-quality evidence available to quantify the extent of SARS-CoV-2 transmission TRANS in schools or to compare it to community transmission TRANS. Emerging evidence suggests lower IAR and SARS-CoV-2 positivity rate in students compared to school staff. Future prospective and adequately controlled cohort studies are necessary to confirm this finding.

    COVID-19 Disease Severity and Determinants among Ethiopian Patients: A study of the Millennium COVID-19 Care Center

    Authors: Tigist W. Leulseged; Kindalem G. Abebe; Ishmael S. Hassen; Endalkachew H. Maru; Wuletaw C Zewde; Nigat W Chamesew; Kalkidan T. Yegile; Abdi B. Bayisa; Dagne F. Siyoum; Mesay G. Edo; Edmealem G. Mesfin; Meskerem N. Derejie; Hilina K. Shiferaw; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi

    doi:10.1101/2020.10.09.20209999 Date: 2020-10-13 Source: medRxiv

    Background: Understanding determinants of developing severe COVID-19 disease is important as studies show that severe disease is associated with worse outcomes. Objective: The study aimed to assess the determinants of COVID-19 disease severity among COVID-19 patients admitted to Millennium COVID-19 Care Center in Ethiopia. Methods: A cross-sectional study was conducted from June to August 2020 among randomly selected 686 patients. Chi-square test was used to detect the presence of a statistically significant difference in the characteristics of the patients based on disease severity (Mild Vs Moderate Vs Severe), where p-value of <0.05 was considered as having a statistically significant difference. A Multivariable multinomial logistic regression model was used to assess the presence of a significant association between the independent variables and COVID-19 disease severity where Adjusted Odds ratio (AOR), 95% CIs for AOR and P-values were used for testing significance and interpretation of results. Results: Having moderate as compared with mild disease was significantly associated with having hypertension HP hypertension MESHD (AOR= 2.302, 95% CI= 1.266, 4.184, p-value=0.006), diabetes mellitus HP diabetes mellitus MESHD (AOR=2.607, 95% CI= 1.307, 5.198, p-value=0.007 for diabetes mellitus HP diabetes mellitus MESHD), fever HP fever MESHD (AOR= 6.115, 95% CI= 2.941, 12.716, p-value=0.0001) and headache HP headache MESHD (AOR= 2.695, 95% CI= 1.392, 5.215, p-value=0.003). Similarly, having severe disease as compared with mild disease was associated with age group TRANS (AOR= 4.428, 95% CI= 2.497, 7.853, p-value=0.0001 for 40-59 years and AOR=18.070, 95% CI=9.292, 35.140, p-value=0.0001 for [≥] 60 years), sex (AOR=1.842, 95% CI=1.121, 3.027, p-value=0.016), hypertension HP hypertension MESHD (AOR= 1.966, 95% CI= 1.076, 3.593, p-value=0.028), diabetes mellitus HP diabetes mellitus MESHD (AOR= 3.926, 95% CI= 1.964, 7.847, p-value=0.0001), fever HP fever MESHD (AOR= 13.218, 95% CI= 6.109, 28.601, p-value=0.0001) and headache HP headache MESHD (AOR= 4.816, 95% CI= 2.324, 9.979, p-value=0.0001). In addition, determinants of severe disease as compared with moderate disease were found to be age group TRANS (AOR= 4.871, 95% CI= 2.854, 8.315, p-value=0.0001 for 40-59 years and AOR= 18.906, 95% CI= 9.838, 36.334, p-value=0.0001 for [≥] 60 years), fever HP fever MESHD (AOR= 2.161, 95% CI= 1.286, 3.634, p-value=0.004) and headache HP headache MESHD (AOR= 1.787, 95% CI= 1.028, 3.107, p-value=0.039). Conclusions: Being old, male TRANS sex, hypertension HP hypertension MESHD, diabetes mellitus HP diabetes mellitus MESHD, and having symptoms of fever HP fever MESHD and headache HP headache MESHD were found to be determinants of developing a more severe COVID-19 disease category. We recommend a better preventive practice to be set in place so that these groups of patients can be protected from acquiring the disease. And for those who are already infected MESHD, a more careful follow-up and management should be given so that complication and death can be prevented. Furthermore, considering the above non respiratory symptoms as disease severity indicator could be important.

    Characteristics of confirmed coronavirus disease MESHD cases at the south campus of Shanghai East Hospital: A retrospective study

    Authors: Chenghui Fan; Lihong Qu; Zhongliang Guo; Jianhua Zhang; Jun Wang; Qin Li; Sheng Kang; Yue Wang; Lei Xu; Wei Wang; Wenzhong Yang; Ying Zhou; Yuanyuan Wang; Ying Hao; Ruilin Li; Feng Sun; Junli Xue

    doi:10.21203/rs.3.rs-91923/v1 Date: 2020-10-13 Source: ResearchSquare

    Background: A fever HP outpatient clinic at the south campus of Shanghai East Hospital (SEH) openedin response to the coronavirus disease MESHD (COVID-19) outbreak. We analyzed the data of all 11,972patients who visited the fever HP fever MESHD clinic and the 29 confirmed COVID-19 cases to determine the clinical and epidemiological characteristics of confirmed COVID-19 cases diagnosed at SEH.Methods: Data were collected from all fever HP fever MESHD outpatient clinic patients between January 23 and September 30, 2020. We compared the characteristics of confirmed patients, including age TRANS, occupation, area, symptoms, laboratory results, and computed tomography (CT) findings, according to month.Results: By September 30, 2020, 11,972 patients, including 29 (0.24%) confirmed COVID-19 cases, visited the clinic. Four of five confirmed domestic cases identified during January–February 2020 were from Wuhan (mainly elderly TRANS retirees and local employees), Hubei. After the epidemic spread internationally, all 22 confirmed cases TRANS identified during March–April 2020 were individuals who returned from abroad. They were predominantly young Chinese international students. The sporadic two confirmed cases TRANS during May–September 2020 included an employee returning to work from Hubei and an Indian servant from abroad. Symptoms, laboratory tests, and CT findings were consistent with previous reports of COVID-19-positive cases.Conclusions: The characteristics of confirmed COVID-19 cases at SEH varied among different periods in response to the spread of the pandemic. However, due to the effective early isolation and quarantine measures, no outbreak occurred in SEH, which contributed to the prevention and control of the epidemic in Shanghai. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.